| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 146 | 2021 |
| Targeting RET kinase in neuroendocrine prostate cancer HR VanDeusen, JR Ramroop, KL Morel, SY Bae, AV Sheahan, Z Sychev, ... Molecular Cancer Research 18 (8), 1176-1188, 2020 | 40 | 2020 |
| Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo KL Morel, RJ Ormsby, E Bezak, CJ Sweeney, PJ Sykes Radiation research 187 (5), 501-512, 2017 | 40 | 2017 |
| The methylation of DNA repeat elements is sex-dependent and temporally different in response to X radiation in radiosensitive and radioresistant mouse strains MR Newman, PJ Sykes, BJ Blyth, E Bezak, MD Lawrence, KL Morel, ... Radiation research 181 (1), 65-75, 2014 | 32 | 2014 |
| The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer LNK Tran, G Kichenadasse, LM Butler, MM Centenera, KL Morel, ... Molecular Cancer Therapeutics 16 (12), 2689-2700, 2017 | 31 | 2017 |
| The role of RB in prostate cancer progression DL Burkhart, KL Morel, AV Sheahan, ZA Richards, L Ellis Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and …, 2019 | 16 | 2019 |
| The combination of metformin and valproic acid has a greater anti-tumoral effect on prostate cancer growth in vivo than either drug alone LNK Tran, G Kichenadasse, KL Morel, TC Lavranos, S Klebe, KM Lower, ... in vivo 33 (1), 99-108, 2019 | 15 | 2019 |
| A single whole-body low dose X-irradiation does not affect L1, B1 and IAP repeat element DNA methylation longitudinally MR Newman, PJ Sykes, BJ Blyth, E Bezak, MD Lawrence, KL Morel, ... PLoS One 9 (3), e93016, 2014 | 14 | 2014 |
| NF-κB blockade with oral administration of dimethylaminoparthenolide (DMAPT), delays prostate cancer resistance to androgen receptor (AR) inhibition and inhibits AR variants KL Morel, AA Hamid, JG Clohessy, N Pandell, L Ellis, CJ Sweeney Molecular Cancer Research 19 (7), 1137-1145, 2021 | 11 | 2021 |
| DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo KL Morel, RJ Ormsby, S Klebe, CJ Sweeney, PJ Sykes Radiation Research 192 (2), 231-239, 2019 | 9 | 2019 |
| Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide KL Morel, RJ Ormsby, EL Solly, LNK Tran, CJ Sweeney, S Klebe, ... Clinical & Experimental Metastasis 35, 649-661, 2018 | 8 | 2018 |
| Evidence that EZH2 deregulation is an actionable therapeutic target for prevention of prostate cancer DL Burkhart, KL Morel, KM Wadosky, DP Labbé, PM Galbo, Z Dalimov, ... Cancer Prevention Research 13 (12), 979-988, 2020 | 7 | 2020 |
| Targeting EZH2 increases therapeutic efficacy of check-point blockade in models of prostate cancer AV Sheahan, KL Morel, DL Burkhart, SC Baca, DP Labbé, K Roehle, ... BioRxiv, 730135, 2019 | 7 | 2019 |
| Abstract B29: Targeting EZH2 and PI3K/mTOR for a novel combination therapeutic strategy in aggressive variant prostate cancer KL Morel, CJ Sweeney, L Ellis Molecular Cancer Research 18 (10_Supplement), B29-B29, 2020 | 1 | 2020 |
| Parthenolide in the Treatment and Prevention of Prostate Cancer K Morel Flinders University, School of Medicine., 2017 | 1 | 2017 |
| MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer B German, JN Singh, MAS Fonseca, DL Burkhart, A Sheahan, H Bergom, ... bioRxiv, 2024 | | 2024 |
| MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer L Ellis, B German, JN Singh, DL Burkhart, A Sheahan, H Bergom, ... bioRxiv, 2024.01. 31.578216, 2024 | | 2024 |
| Loss of tristetraprolin activates NF-κB induced phenotypic plasticity and primes transition to lethal prostate cancer KL Morel, AA Hamid, BG Falcón, JS Nanda, S Linder, AM Bergman, ... bioRxiv, 2022.08. 05.500896, 2022 | | 2022 |
| Combined loss of tristetraprolin (TTP) and PTEN leads to aggressive prostate cancer and hypersensitivity to nuclear factor kappa B (NFkB) inhibition CJ Sweeney, K Morel, A Hamid, L Ellis Cancer Research 82 (12_Supplement), 5295-5295, 2022 | | 2022 |
| Targeting EZH2 and PI3K/mTOR for a novel combination therapeutic strategy in aggressive variant prostate cancer. KL Morel, CJ Sweeney, L Ellis MOLECULAR CANCER RESEARCH 18 (10), 56-56, 2020 | | 2020 |
